A Comprehensive Investigation of the Interactions between Proteins and Ligands in the Crystal Structures of Mycobacterium Tuberculosis

Mycobacterium tuberculosis (MTB), an acid-fast aerobic bacterium that may grow on gram stain as either a gram-positive or gram-negative bacterium, is the disease-causing agent of (TB). Rifampin, isoniazid, pyrazinamide and ethambutol, first-line anti-tubercular drugs, can all have hepatotoxic side effects. The new medicine needs to work through novel mode action target, be more active than presently available treatments, shorten course treatment for MDR-TB XDR-TB, also against both latent bacteria, does not interact with antiretroviral medications because many TB patients HIV. Additionally, it must well other anti-TB form at least effective three-drug regimen. This article discusses analysis few FDA-approved their binding locations respective targeted proteins. mainly focuses amino acids proteins are responsible formation interactions drug molecule. So, researchers modify existing drugs derivatives construct molecule according sites enzymes corresponding mycobacterium tuberculosis.